Utilization of antidepressants in taiwan: A nationwide population-based survey from 2000 to 2009

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 9, 2012, Pages 980-988

  Wu, Chi Shin ^a,b,c   Shau, Wen Yi ^d   Chan, Hung Yu ^c,e,f   Lee, Yen Chieh ^b,g   Lai, Yun Ju ^h   Lai, Mei Shu ^a,b  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d Center for Drug Evaluation   (Taiwan)

^e Taoyuan Mental Hospital   (Taiwan)

^f CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

^g CATHAY GENERAL HOSPITAL   (Taiwan)

^h CARDINAL TIEN HOSPITAL   (Taiwan)

Author keywords

Antidepressant; Taiwan; Utilization

Indexed keywords

ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADJUSTMENT DISORDER; ADOLESCENT; ADULT; AGED; ANXIETY DISORDER; ARTICLE; CHILD; DRUG UTILIZATION; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; POPULATION RESEARCH; PRESCHOOL CHILD; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; SLEEP DISORDER; TAIWAN;

ADJUSTMENT DISORDERS; ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIDEPRESSIVE AGENTS; CHILD; DATABASES, FACTUAL; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MENTAL DISORDERS; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; SLEEP DISORDERS; TAIWAN; YOUNG ADULT;

EID: 84865861770     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3255     Document Type: Article

References (40)

1. Chien IC, Bih SH, Chou YJ, Lin CH, Lee WG, Chou P. Trends in the use of psychotropic drugs in Taiwan: a population-based national health insurance study, 1997-2004. Psychiatr Serv 2007; 58: 554-557.
2. Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry 2009; 66: 848-856.
3. Patten SB, Esposito E, Carter B. Reasons for antidepressant prescriptions in Canada. Pharmacoepidemiol Drug Saf 2007; 16: 746-752.
4. Raymond CB, Morgan SG, Caetano PA. Antidepressant utilization in British Columbia from 1996 to 2004: increasing prevalence but not incidence. Psychiatr Serv 2007; 58: 79-84.
5. Trifiro G, Barbui C, Spina E, et al. Antidepressant drugs: prevalence, incidence and indication of use in general practice of Southern Italy during the years 2003-2004. Pharmacoepidemiol Drug Saf 2007; 16: 552-559.
6. Sheehan DV, Keene MS, Eaddy M, Krulewicz S, Kraus JE, Carpenter DJ. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs 2008; 22: 963-973.
7. Harman JS, Edlund MJ, Fortney JC. Trends in antidepressant utilization from 2001 to 2004. Psychiatr Serv 2009; 60: 611-616.
8. Stafford RS, MacDonald EA, Finkelstein SN. National patterns of medication treatment for depression, 1987 to 2001. Prim Care Companion J Clin Psychiatry 2001; 3: 232-235.
9. Gardarsdottir H, Heerdink ER, van Dijk L, Egberts AC. Indications for antidepressant drug prescribing in general practice in the Netherlands. J Affect Disord 2007; 98: 109-115.
10. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008; 4: 487-504.
11. Carta MG, Balestrieri M, Murru A, Hardoy MC. Adjustment disorder: epidemiology, diagnosis and treatment. Clin Pract Epidemiol Ment Health 2009; 5: 15.
12. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol 2009; 16: 968-981.
13. Chou R, Huffman LH. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med 2007; 147: 505-514.
14. Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006; 13: 1153-1169.
15. Hauser W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome-a systematic review. Eur J Pain 2010; 14: 5-10.
16. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64: 1427-1443.
17. Drossman DA, Dumitrascu DL. Rome III: New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis 2006; 15: 237-241.
18. Corcos J, Gajewski J, Heritz D, et al. Canadian Urological Association guidelines on urinary incontinence. Can J Urol 2006; 13: 3127-3138.
19. Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010; 57: 804-814.
20. Chen Y, Kelton CM, Jing Y, Guo JJ, Li X, Patel NC. Utilization, price, and spending trends for antidepressants in the US Medicaid Program. Res Social Adm Pharm 2008; 4: 244-257.
21. The Bureau of National Health Insurance. http://www.nhi.gov.tw/english/index.aspx [1 November 2011].
22. WHO Collaborating Centre for Drug Statistic Methodology. Guidelines for ATC Classification and DDD Assignment. WHO: Oslo, 2009.
23. Delaney JA, Oddson BE, McClelland RL, Psaty BM. Estimating ethnic differences in self-reported new use of antidepressant medications: results from the multi-ethnic study of atherosclerosis. Pharmacoepidemiol Drug Saf 2009; 18: 545-553.
24. Hwu HG, Yeh EK, Chang LY. Prevalence of psychiatric disorders in Taiwan defined by the Chinese Diagnostic Interview Schedule. Acta Psychiatr Scand 1989; 79: 136-147.
25. Chien IC, Chou YJ, Lin CH, Bih SH, Chou P. Prevalence of psychiatric disorders among National Health Insurance enrollees in Taiwan. Psychiatr Serv 2004; 55: 691-697.
26. US Food and Drug Administration Summary minutes of the CDER psychopharmacologic Drugs Advisory Committee and the FDA Pediatric Advisory Committee, 2004.
27. Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005; 330: 396.
28. Libby AM, Orton HD, Valuck RJ. Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry 2009; 66: 633-639.
29. Meijer WE, Heerdink ER, Nolen WA, Herings RM, Leufkens HG, Egberts AC. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004; 164: 2367-2370.
30. Nutt DJ. Death and dependence: current controversies over the selective serotonin reuptake inhibitors. J Psychopharmacol 2003; 17: 355-364.
31. Liu SZ, Romeis JC. Changes in drug utilization following the outpatient prescription drug cost-sharing program-evidence from Taiwan's elderly. Health Policy 2004; 68: 277-287.
32. Chang HJ, Huang N, Lee CH, Hsu YJ, Hsieh CJ, Chou YJ. The impact of the SARS epidemic on the utilization of medical services: SARS and the fear of SARS. Am J Public Health 2004; 94: 562-564.
33. Exeter D, Robinson E, Wheeler A. Antidepressant dispensing trends in New Zealand between 2004 and 2007. Aust N Z J Psychiatry 2009; 43: 1131-1140.
34. Sim K, Lee NB, Chua HC, et al. Newer antidepressant drug use in East Asian psychiatric treatment settings: REAP (Research on East Asia Psychotropic Prescriptions) Study. Br J Clin Pharmacol 2007; 63: 431-437.
35. Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000; 403: 17-25.
36. Spina E, Scordo MG. Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 2002; 19: 299-320.
37. Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr 2008; 13: 855-870.
38. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 2005; 66: 469-476.
39. Werneke U, Northey S, Bhugra D. Antidepressants and sexual dysfunction. Acta Psychiatr Scand 2006; 114: 384-397.
40. Fink HA, MacDonald R, Rutks IR, Wilt TJ. Trazodone for erectile dysfunction: a systematic review and meta-analysis. BJU Int 2003; 92: 441-446.